Frédéric Frippiat - Infectious Diseases

Author Information

Frédéric Frippiat is a researcher affiliated with the Division of Infectious Diseases at the Department of Internal Medicine, University Hospital of Liège, located in Liège, Belgium. His work is primarily focused on infectious diseases, with a particular interest in the pharmacokinetics of antibiotics, management of infective endocarditis, and the implications of drug interactions in people living with HIV.

Research Contributions

Frédéric Frippiat has made significant contributions to the field of infectious diseases, particularly in understanding the pharmacokinetics and therapeutic use of antibiotics such as temocillin, linezolid, ceftazidime-avibactam, and cefepime. His research often explores the clinical outcomes and adverse effects associated with these treatments. Additionally, Frippiat has investigated the impacts of HIV medication regimens on lipid profiles and cardiovascular risk. His work also extends to the study of SARS-CoV-2 transmission among school children and surgical management of infective endocarditis caused by bacterial infections.

Aliases

Frédéric Frippiat is also known in his publications and professional circles under various aliases, including F Frippiat and F. Frippiat. These aliases are used interchangeably in different research articles and professional documents.

Publication and Citation Metrics

Metric	Value
Total Citation Count	1383
h-index	15
Total Paper Count	82

Publications:

Modelled Target Attainment after Temocillin Treatment in Severe Pneumonia: Systemic and Epithelial Lining Fluid Pharmacokinetics of Continuous versus Intermittent Infusions

DOI: 10.1128/aac.02052-21

Year: 2022

Clinical Use and Adverse Drug Reactions of Linezolid: A Retrospective Study in Four Belgian Hospital Centers

DOI: 10.3390/antibiotics10050530

Year: 2021

Continuous Infusion, Therapeutic Drug Monitoring and Outpatient Parenteral Antimicrobial Therapy with Ceftazidime-Avibactam: a Retrospective Cohort Study.

DOI: 10.1016/j.jgar.2021.04.015

Year: 2021

Impact of switch from tenofovir disoproxil fumarate-based regimens to tenofovir alafenamide-based regimens on lipid profile, weight gain and cardiovascular risk score in people living with HIV

DOI: 10.1186/s12879-021-06479-9

Year: 2021

Transmission of SARS-CoV-2 After COVID-19 Screening and Mitigation Measures for Primary School Children Attending School in Liège, Belgium

DOI: 10.1001/jamanetworkopen.2021.28757

Year: 2021

Surgical management of Staphylococcus capitis prosthetic valve infective endocarditis: Retrospective review of a 10-year single center experience and review of the literature.

DOI: 10.1016/j.jiph.2020.09.010

Year: 2020

Continuous infusion of cefepime and neurotoxicity: a retrospective cohort study.

DOI: 10.1016/j.cmi.2020.07.003

Year: 2020

Streptococcus agalactiae infective endocarditis: analysis of eight surgical cases from a single centre

DOI: 10.1080/23744235.2020.1863460

Year: 2020

Evolution of Drug Interactions With Antiretroviral Medication in People With HIV

DOI: 10.1093/ofid/ofaa416

Year: 2020

[Streptococcus agalactiae infective endocarditis].

DOI:

Year: 2020

What Skills are Essential for ID Specialists?

How Can These Diseases Be Prevented?

Why is the Global Fund Important?

What is Bovine Tuberculosis?

What precautions are necessary during air travel?

What are the Strengths and Limitations?

What Are the Global Efforts to Combat Malaria?

What Role Does the FDA Play in Diagnostic Testing?

Can STIs Affect Pregnancy?

What are the Risk Factors for Developing Dengue Hemorrhagic Fever?

Partnered Content Networks

Relevant Topics